OTCEquity is a premier site for updated news and financial information regarding penny stocks and small cap companies. We offer a free newsletter, articles about penny stock trading, otc bulletin board analytical data and original news stories about the penny stock companies you are interested in.
Less than a month ago shares of Raptor Pharmaceutical Corp. (NASDAQ: RPTP) were trading at a 52-week high of 7.67 following news that the FDA had approved their nephropathic cystinosis drug, Procysbi, a twice-daily oral medication that puts it in … Continue reading →
While it has been more than a week since Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) released their first quarter financial and operational results it was today that the biopharmaceutical company focused on the development and commercialization of products for the treatment … Continue reading →
Alimera Sciences, Inc. (NASDAQ: ALIM) surged to a 52-week high of 3.98 on Monday, this after closing Friday’s trading session at 3.11, while volume in the biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals … Continue reading →
Posted in Articles, NASDAQ
|
Tagged alim, alimera sciences, biopharmaceutical, diabetes, diabetic, dme, fda, iluvien, investors, pdufa
|
The FDA’s decision to hold off on granting approval for an implant to treat addiction to heroin and prescription painkillers from Titan Pharmaceuticals, Inc. (OTCBB: TTNP) is a bitter reminder to investors that the agency doesn’t always follow the recommendation … Continue reading →
Following the release of positive data involving their drugs GR-MD-02 and GM-CT-01 that are intended to inhibit galectin proteins as a means of treating liver fibrosis shares of Galectin Therapeutics, Inc. (NASDAQ: GALT) spiked to a 52-week high of 5.22 … Continue reading →
There are plenty of investors placing their bets on Aveo Pharmaceuticals, Inc. (NASDAQ: AVEO) as the cancer therapeutics company, doing business as Aveo Oncology, nears the date in which they will face the FDA’s Oncologic Drugs Advisory Committee (ODAC) for … Continue reading →
Posted in Articles, NASDAQ
|
Tagged aveo, aveo pharmaceuticals, cancer therapeutics, fda, investors, nda, oncology, onx, rcc, tivozanib
|
Aided by a corporate update issued earlier today trading volume in Easton Pharmaceuticals Inc. (PINKSHEETS: EAPH) has pushed past the 1.4 million mark in late day action, a significant increase over their 100-day average of 170,000. For those investors who … Continue reading →
Investors tend to take notice when an FDA advisory panel recommends approval for a particular treatment being developed by a biopharmaceutical company and yesterday’s late news regarding Titan Pharmaceuticals Inc. (OTCBB: TTNP) and the advancement of their subdermal implant of … Continue reading →
The year just keeps getting better for Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) and for those shareholders that managed to build a big position just over four months ago when shares were trading as low as 1.80. On Thursday ACAD shot … Continue reading →
Back on January 30, 2013 A.P. Pharma, Inc. (OTCBB: APPA) was trading at a 52-week high of 0.8870 due in large part to speculation that their lead product candidate for the prevention of chemotherapy-induced nausea, APF530, would manage to navigate … Continue reading →
